Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Director Sells 7,144 Shares of Stock

Key Points

• Director Howard Welgus sold 7,144 shares of Arcutis on May 1 at an average price of $22.99 for total proceeds of $164,240.56 under a pre‑arranged Rule 10b5‑1 plan, reducing his ownership by 17.98% to 32,600 shares.
• Arcutis beat quarterly estimates, reporting $0.13 EPS vs. $0.03 expected and $129.5M revenue vs. $110.79M, but the company still shows a negative return on equity (‑10.26%) and a negative net margin (‑4.29%).
• Stock and market context: ARQT traded around $23.42 (down $0.07) with a $2.93B market cap and negative P/E, while analysts give a consensus "Moderate Buy" rating with a $34 consensus price target.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) Director Howard Welgus sold 7,144 shares of the company's stock in a transaction on Friday, May 1st. The stock was sold at an average price of $22.99, for a total value of $164,240.56. Following the sale, the director owned 32,600 shares of the company's stock, valued at $749,474. This trade represents a 17.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arcutis Biotherapeutics Stock Down 0.3%

Shares of NASDAQ ARQT traded down $0.07 during mid-day trading on Tuesday, reaching $23.42. 850,225 shares of the company were exchanged, compared to its average volume of 1,022,486. The company has a quick ratio of 2.99, a current ratio of 3.17 and a debt-to-equity ratio of 0.57. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of -167.27 and a beta of 1.58. Arcutis Biotherapeutics, Inc. has a 1 year low of $12.42 and a 1 year high of $31.77. The firm has a 50-day moving average of $23.82 and a 200 day moving average of $25.75.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.10. The firm had revenue of $129.50 million during the quarter, compared to analysts' expectations of $110.79 million. Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of 4.29%. On average, research analysts expect that Arcutis Biotherapeutics, Inc. will post 0.18 earnings per share for the current year.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Focus Partners Wealth raised its stake in shares of Arcutis Biotherapeutics by 0.8% in the third quarter. Focus Partners Wealth now owns 65,196 shares of the company's stock worth $1,237,000 after purchasing an additional 490 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Arcutis Biotherapeutics by 1.8% in the third quarter. Arizona State Retirement System now owns 31,685 shares of the company's stock worth $597,000 after purchasing an additional 568 shares during the last quarter. Schroder Investment Management Group raised its stake in shares of Arcutis Biotherapeutics by 1.1% in the fourth quarter. Schroder Investment Management Group now owns 57,136 shares of the company's stock worth $1,604,000 after purchasing an additional 594 shares during the last quarter. AlphaQuest LLC raised its stake in shares of Arcutis Biotherapeutics by 5.7% in the third quarter. AlphaQuest LLC now owns 12,603 shares of the company's stock worth $238,000 after purchasing an additional 682 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Arcutis Biotherapeutics by 124.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company's stock worth $37,000 after purchasing an additional 698 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms have commented on ARQT. Wall Street Zen cut Arcutis Biotherapeutics from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 14th. Mizuho decreased their price target on Arcutis Biotherapeutics from $37.00 to $35.00 and set an "outperform" rating for the company in a research note on Monday, March 2nd. Guggenheim increased their price target on Arcutis Biotherapeutics from $34.00 to $35.00 and gave the company a "buy" rating in a research note on Friday, February 27th. HC Wainwright increased their price target on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Arcutis Biotherapeutics in a research note on Friday, March 27th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $34.00.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.